OMEROS CORP Contract with Customer, Receivable, Credit Loss Expense (Reversal)
OMEROS CORP (OMER) reported Contract with Customer, Receivable, Credit Loss Expense (Reversal) of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ContractWithCustomerReceivableCreditLossExpenseReversal · last filed 2026-08-12
- OMEROS CORP contract with customer, receivable, credit loss expense (reversal) for the quarter ending 2026-06-30 was $0.00.
- OMEROS CORP contract with customer, receivable, credit loss expense (reversal) for the quarter ending 2026-03-31 was $0.00.
| Period end | Contract with Customer, Receivable, Credit Loss Expense (Reversal) 3 month | Contract with Customer, Receivable, Credit Loss Expense (Reversal) 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |